SpringerLink
Log in

Cabotegravir/rilpivirine

Lack of efficacy

  • Case report
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price includes VAT (Germany)

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Mesa D, et al. Real-World Outcomes with Cabotegravir/Rilpivirine: Does Duration of Pre-treatment Viral Suppression Matter?. Open Forum Infectious Diseases 10 (Suppl. 2): S736 abstr. 1589, Dec 2023. Available from: URL: https://dx.doi.org/10.1093/ofid/ofad500.1424 [abstract]

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Cabotegravir/rilpivirine. Reactions Weekly 2005, 191 (2024). https://doi.org/10.1007/s40278-024-57284-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-024-57284-6

Search

Navigation